Abstract
A synthetic genetic chain was created—a two-promoter integrator, the activity of the output signal of which is high only with the high activity of two promoters at the input of the chain. The integrator is shown to work by the example of cancer-specific promoters of the human survivin and telomerase genes that can be used for specific transcription of target genes in tumor cells. To create the integrator, we used the well-known TET-ON 3G transactivator, regulated by doxycycline.
Similar content being viewed by others
REFERENCES
Li Y., Idamakanti N., Arroyo T., Thorne S., Reid T., Nichols S., VanRoey M., Colbern G., Nguyen N., Tam O., Working P., Yu D.C. 2005. Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models. Clin. Cancer Res. 11 (24, Pt. 1), 8845‒8855.
Ryan P.C., Jakubczak J.L., Stewart D.A., Hawkins L.K., Cheng C., Clarke L.M., Ganesh S., Hay C., Huang Y., Kaloss M., Marinov A., Phipps S.S., Reddy P.S., Shirley P.S., Skripchenko Y., et al. 2004. Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer. Cancer Gene Ther.11 (8), 555‒569.
Liu Y., Zeng Y., Liu L., Zhuang C., Fu X., Huang W., Cai Z. 2014. Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells. Nat. Commun.5, 5393.
Jerome V., Muller R. 1998. Tissue-specific, cell cycle-regulated chimeric transcription factors for the targeting of gene expression to tumor cells. Hum. Gene Ther.9 (18), 2653–2659.
Jérôme V., Müller R. 2001. A synthetic leucine zipper-based dimerization system for combining multiple promoter specificities. Gene Ther.8 (9), 725‒729.
Nissim L., Bar-Ziv R.H. 2010. A tunable dual-promoter integrator for targeting of cancer cells. Mol. Syst. Biol.6, 444.
Wang H., Liu J., Yuet K.P., Hill A.J., Sternberg P.W. 2018. Split cGAL, an intersectional strategy using a split intein for refined spatiotemporal transgene control in Caenorhabditis elegans.Proc. Natl. Acad. Sci. U. S. A.115 (15), 3900‒3905.
Scott E.K., Mason L., Arrenberg A.B., Ziv L., Gosse N.J., Xiao T., Chi N.C., Asakawa K., Kawakami K., Baier H. 2007. Targeting neural circuitry in zebrafish using GAL4 enhancer trapping. Nat. Methods.4 (4), 323–326.
Shay J.W., Bacchetti S. 1997. A survey of telomerase activity in human cancer. Eur. J. Cancer.33 (5), 787‒791.
Altieri D.C. 2008. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer.8 (1), 61‒70.
Zettler J., Schütz V., Mootz H.D. 2009. The naturally split Npu DnaE intein exhibits an extraordinarily high rate in the protein trans-splicing reaction. FEBS Lett.583 (5), 909‒914.
Murofushi Y., Nagano S., Kamizono J., Takahashi T., Fujiwara H., Komiya S., Matsuishi T., Kosai K. 2006. Cell cycle-specific changes in hTERT promoter activity in normal and cancerous cells in adenoviral gene therapy: A promising implication of telomerase-dependent targeted cancer gene therapy. Int. J. Oncol.29 (3), 681‒688.
Funding
This study was financially supported by the Russian Foundation for Basic Research (project no. 18-04-00212 A). Work on the creation of genetic engineering structures was carried out with the support of the Russian Science Foundation, project no. 19-14-00112.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This article does not contain any research involving humans or animals as subjects of research.
Conflict of interest. The authors declare they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Khodarovich, Y.M., Rakhmaninova, D.D., Barishnikova, A.M. et al. Doxycycline Sensitive Two-Promoter Integrator Based on the TET-ON 3G Transactivator. Mol Biol 54, 269–273 (2020). https://doi.org/10.1134/S0026893320020053
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S0026893320020053